Guardant Health Acquires MetaSight, Raises 2026 Revenue Growth Outlook
Guardant Health will acquire MetaSight to expand its oncology diagnostics by integrating MetaSight’s AI-driven imaging platform into its liquid biopsy offerings. The company simultaneously issued a positive financial outlook for 2026, forecasting mid-teens revenue growth and targeting adjusted EBITDA breakeven by year-end.
1. Acquisition Details
Guardant Health announced it will acquire MetaSight in an all-cash transaction for an undisclosed amount, with the deal expected to close in the second quarter. MetaSight’s AI-driven imaging technology will be integrated into Guardant’s liquid biopsy platform to enhance early cancer detection and diagnostic accuracy.
2. Strategic Rationale
By combining MetaSight’s imaging analytics with Guardant’s genomic assays, management aims to develop a unified oncology diagnostics suite that leverages both blood-based biomarkers and advanced image recognition. This strategic move is designed to strengthen Guardant’s competitive position in precision oncology and broaden its product pipeline.
3. 2026 Financial Projections
Alongside the acquisition announcement, Guardant raised its full-year 2026 guidance to forecast mid-teens percentage revenue growth, driven by expanded diagnostic offerings and expected synergies. The company also targets adjusted EBITDA breakeven by year-end, marking a significant step toward sustained profitability.